Molecular, clinical, and therapeutic determinants of outcome in <i>NPM1</i>-mutated AMLJad Othman, Richard Dillon, Charlotte S. Wilhelm-Benartzi et al.|Blood|2024Cited by 78
Postinduction molecular MRD identifies patients with <i>NPM1</i> AML who benefit from allogeneic transplant in first remissionJad Othman, Nigel H. Russell, Richard Dillon et al.|Blood|2024Cited by 75
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trialJad Othman, Nigel H. Russell, Emily L Hinson et al.|Blood Advances|2023Cited by 53
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With <i>NPM1</i> and <i>FLT3</i> MutationsNigel H. Russell, Shankara Paneesha, Ashok Roy et al.|Journal of Clinical Oncology|2024Cited by 40
Venetoclax–based low intensity therapy in molecular failure of <i>NPM1</i>-mutated AMLCarlos Jiménez‐Chillón, Richard Dillon, Steven Knapper et al.|Blood Advances|2023Cited by 29